Elisabeth Lindner
Overview
Explore the profile of Elisabeth Lindner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindner E, Schoberl T, Desantis A, Gail A
Conscious Cogn
. 2025 Mar;
130:103837.
PMID: 40058061
Motor theories propose that predicting sensory consequences of one's own actions reduces perception and neural processing of these action-effects, a phenomenon known as sensory attenuation, considered an implicit measure of...
2.
Lindner E, Desantis A, Cheng F, Gail A
Neuroimage
. 2024 Jul;
297:120717.
PMID: 38971482
Self-initiated sensory action effects are widely assumed to lead to less intense perception and reduced neural responses compared to externally triggered stimuli (sensory attenuation). However, it is unclear if sensory...
3.
Ariceta G, Collard L, Abroug S, Moochhala S, Gould E, Boussetta A, et al.
Pediatr Nephrol
. 2022 May;
38(2):403-415.
PMID: 35552824
Background: Primary hyperoxalurias (PHs) are rare genetic diseases that increase the endogenous level of oxalate, a waste metabolite excreted predominantly by the kidneys and also the gut. Treatments aim to...
4.
Milliner D, Cochat P, Hulton S, Harambat J, Banos A, Dehmel B, et al.
Pediatr Nephrol
. 2021 Jan;
36(7):1785-1793.
PMID: 33515281
Background: In patients with primary hyperoxaluria (PH), endogenous oxalate overproduction increases urinary oxalate excretion, leading to compromised kidney function and often kidney failure. Highly elevated plasma oxalate (Pox) is associated...
5.
Hoppe B, Pellikka P, Dehmel B, Banos A, Lindner E, Herberg U
Nephrol Dial Transplant
. 2020 Aug;
36(8):1464-1473.
PMID: 32810261
Background: In primary hyperoxaluria Type 1 (PH1), endogenous oxalate overproduction significantly elevates urinary oxalate excretion, resulting in recurrent urolithiasis and/or progressive nephrocalcinosis and often early end-stage renal disease (ESRD). In...
6.
Stokes F, Acquaviva-Bourdain C, Hoppe B, Lieske J, Lindner E, Toulson G, et al.
Urolithiasis
. 2020 May;
48(6):473-480.
PMID: 32472220
Measurement of oxalate in the blood is essential for monitoring primary hyperoxaluria patients with progressive renal impairment and on dialysis prior to transplantation. As no external quality assurance scheme is...
7.
Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton S, Vant Hoff W, et al.
Pediatr Nephrol
. 2016 Dec;
32(5):781-790.
PMID: 27924398
Background: Primary hyperoxaluria (PH) is a rare, genetic disorder which involves the overproduction of endogenous oxalate, leading to hyperoxaluria, recurrent urolithiasis and/or progressive nephrocalcinosis and eventually resulting in kidney failure...
8.
Clifford-Mobley O, Sjogren A, Lindner E, Rumsby G
Urolithiasis
. 2016 Feb;
44(4):333-7.
PMID: 26857252
Hyperoxaluria is a well-recognised risk factor for urolithiasis and patients with primary hyperoxaluria (PH) gradually build up calcium oxalate deposits leading to chronic kidney disease. Efforts to improve treatment for...
9.
Kaczirek K, Ciuleanu T, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, et al.
Clin Colorectal Cancer
. 2015 Feb;
14(2):91-8.
PMID: 25666295
Background: This updated analysis of the CECOG/CORE 1.2.002 study investigated the association between clinical outcome and RAS and BRAF mutations in metastatic colorectal cancer (mCRC) patients treated with FOLFOX4 plus...
10.
Kahan Z, Spanik S, Wagnerova M, Skacel T, Planko B, Fitzthum E, et al.
Breast Cancer Res Treat
. 2008 Jan;
112(3):557-63.
PMID: 18189160
Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens,...